Form 8-K - Current report:
SEC Accession No. 0000950170-23-058254
Filing Date
2023-11-02
Accepted
2023-11-02 16:21:47
Documents
13
Period of Report
2023-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acad-20231102.htm   iXBRL 8-K 47569
2 EX-99.1 acad-ex99_1.htm EX-99.1 276486
  Complete submission text file 0000950170-23-058254.txt   454337

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acad-20231102_pre.xml EX-101.PRE 9908
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acad-20231102_lab.xml EX-101.LAB 13474
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acad-20231102.xsd EX-101.SCH 2481
7 EXTRACTED XBRL INSTANCE DOCUMENT acad-20231102_htm.xml XML 4760
Mailing Address 12830 EL CAMINO REAL SUITE 400 SAN DIEGO CA 92130
Business Address 12830 EL CAMINO REAL SUITE 400 SAN DIEGO CA 92130 858-558-2871
ACADIA PHARMACEUTICALS INC (Filer) CIK: 0001070494 (see all company filings)

EIN.: 061376651 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50768 | Film No.: 231372688
SIC: 2834 Pharmaceutical Preparations